ITGAM and neoplasm: When spleen extracts were analyzed for MDSCs, there was no significant change in CD11b+Gr1+ cells in spleens following MBQ-167 treatment; however, tumor MDSCs were significantly reduced by ~57% in response to MBQ- 167 treatment.